Life sciences company focusing on research and development of psychedelics medicines Lobe Life Sciences (CSE: LOBE) (OTCMKTS: GTSIF) announced having entered into a production and supply agreement with biotechnology company specializing on research and development of psychopharmacological products from plants and fungi HAVN Life Sciences (CSE: HAVN) (OTC: HAVLF).
In the deal, Lobe will be supplying HAVN with consumer packaged goods products of Vitamind, a company it recently acquired. These goods include plant-based compounds and non-psychoactive mushrooms from Vitamind’s line of natural health products.
Chief Executive Officer and Director at Lobe, Philip Young, says this agreement deal will with HAVN is a milestone in the company’s continuing efforts to help promote better brain health.
“We are very happy to enter into this agreement with a partner that is harmoniously dedicated to development of innovative products. Our agreement also reflects Lobe’s continued ability to collaborate and execute on transactions providing value to shareholders,” said Young.
Vitamind is a company specializing in a brand of non-psychedelic functional mushroom products which include three product lines focusing on boosting immune response and increasing mental clarity.
Lobe Life Sciences acquired Vitamind earlier in the month in a deal closed on May 4.